Please ensure Javascript is enabled for purposes of website accessibility

Can Intuitive Surgical Be the Tesla of Healthcare?

By Eric Cuka – Sep 24, 2021 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Tesla is using robotics and artificial intelligence to dominate the electric vehicle industry. Can Intuitive Surgical replicate that success in hospitals?

In today's video, I continue my series on high-growth artificial intelligence. I have done my best to find the highest-growth companies in a variety of sectors with disruptive growth trends. Last time, I discussed how Square is leveraging artificial intelligence and machine learning to improve Cash App and combat deepfake AI. Today, I'm providing stock analysis on what I consider to be the best robotic surgery company, Intuitive Surgical (ISRG -0.93%).

Intuitive Surgical was hurt by the COVID-19 pandemic, but the company has been firing on all cylinders in 2021. This makes it not only a recovery play, but also a solid long-term investment. Intuitive Surgical reported earnings in July, and it announced shipment of 328 new da Vinci Surgical Systems, an increase of 84% compared to the same quarter last year. It grew its install base to 6,335 systems as of June 30, 2021, an increase of 10% versus the same quarter in 2020. This means many of the systems shipped have not been installed, which could create accelerated growth in the coming quarters. 

Intuitive Surgical has a healthy balance sheet, and the company has performed over 8.5 million surgical procedures since its inception in 1995. It has a first-mover edge in the robotic surgery field, which provides the company with a tremendous competitive advantage, especially when you consider the AI portion of the business, which improves as it receives and evaluates more data, like Tesla's (TSLA -6.37%). Perhaps most importantly, Intuitive Surgical's business thrives off its recurring revenue model. In fact, over 75% of its revenue is recurring, which is explained in the video. 

To top things off, Intuitive Surgical recently announced a 3-for-1 stock split, and shares are expected to start trading on a split-adjusted basis on Oct. 5th. Of course, you do not typically buy a stock solely because of a stock split. If you cut a pizza into eight slices, you still have one pizza. With that said, lower share prices can equate to more pin action because of options contracts and psychological considerations, and I think the company looks attractive here as a long-term investment.

In the video below, I provide concise, deep-dive analysis into Intuitive Surgical's business and provide opinions on the stock. Please watch for more information, and don't forget to subscribe to the channel and take a look at the entire AI video series. 

*Stock prices used in the below video were during the trading day of Sept. 23, 2021. The video was published on Sept. 23, 2021.

Eric Cuka owns shares of Intuitive Surgical and Tesla. The Motley Fool owns shares of and recommends Intuitive Surgical and Tesla. The Motley Fool recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy. Eric is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Stocks Mentioned

Intuitive Surgical Stock Quote
Intuitive Surgical
ISRG
$269.72 (-0.93%) $-2.53
Tesla Stock Quote
Tesla
TSLA
$182.45 (-6.37%) $-12.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.